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ABSTRACT
The aim of this study was to evaluate a 54-kDa recombinant protein encoded by the CPn0980 gene for
use in a Chlamydia pneumoniae-speciﬁc ELISA. The ability of this afﬁnity-puriﬁed protein to detect C.
pneumoniae-speciﬁc antibodies was evaluated with a panel of 105 serum samples from 62 patients with
community-acquired pneumonia. The results of this assay were compared with those obtained with a
direct PCR-based detection assay and an outer-membrane complex-based immunoassay. The 54-kDa
protein induced speciﬁc antibodies following infection of humans, and the recombinant 54-kDa ELISA
detected anti-C. pneumoniae IgG and ⁄ or IgM antibodies with a sensitivity of 66.7% and a speciﬁcity of
79.2% compared with the direct PCR-based detection assay.
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INTRODUCTION
Chlamydia pneumoniae is a common cause of
community-acquired respiratory infection in
adults and children [1], and is implicated in
chronic disease processes such as asthma [2] and
cardiovascular disease [3]. The potential impact of
C. pneumoniae infection on public health, partic-
ularly through its association with atherosclerosis,
makes it important to study immunodominant
candidate antigens for future diagnostic and
vaccination strategies. There are currently no
totally satisfactory serological methods for the
diagnosis of C. pneumoniae infection. However,
during a recent workshop concerning the stand-
ardisation of C. pneumoniae diagnostic methods,
the CDC recommended that the microimmuno-
ﬂuorescence (MIF) test be considered as the
reference serological test, despite the poor pre-
dictive value of a single high IgG titre [4].
Some studies have suggested that the MIF test
is less sensitive and speciﬁc than generally
thought, and that some C. pneumoniae IgM or
IgG reactivity might be caused by heterotypic
antibodies [5,6]. It has also been shown that > 50%
of children with respiratory illness infected with
C. pneumoniae fail to develop any antibodies
detectable by MIF [6]. Therefore, the identiﬁcation
of new C. pneumoniae antigens, which might be
useful for the development of new serodiagnostic
assays, is of great importance. Several ELISAs
based on different C. pneumoniae antigens, such as
recombinant major outer-membrane protein
(MOMP) or outer-membrane protein (OMP) 2,
OMP4 or OMP5, are already available commer-
cially.
The 53–54-kDa protein (P54), encoded by the
CPn0980 gene, is speciﬁc to C. pneumoniae (Gen-
Bank AE001363-contig AE001678.1). This protein,
of unknown function, may correspond to the C.
pneumoniae-speciﬁc 54-kDa immunodominant
antigen identiﬁed previously by western blot
[7,8]. Antibodies against this protein have been
shown by western blot to be very sensitive for the
serodiagnosis of acute C. pneumoniae infections
[9]. The CPn0980 gene has been cloned and the
recombinant protein (P54) has been puriﬁed. In
the present study, the diagnostic value of P54 was
evaluated by ELISA in a population of patients
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with community-acquired respiratory infections.
The sensitivity and speciﬁcity of anti-P54 IgG, IgA
and IgM antibodies were determined in relation
to a direct PCR-based detection assay and an
outer-membrane complex-based ELISA.
MATERIALS AND METHODS
Human specimens
Dacron swabs were used to obtain posterior nasopharyngeal
specimens from 62 patients (median age 42 years; range 20–
73 years; 23 males and 39 females) with community-acquired
respiratory infections, diagnosed on the basis of an infectious
syndrome accompanied by productive coughing, increased
mucoid or mucopurulent expectorations, and slight bronchial
rale. None of the patients had serological evidence of C.
trachomatis infection. Overall, 56 specimens were taken within
24 h of hospital admission, placed in 2 mL of sucrose-phos-
phate transport medium, and stored at ) 80C until use. Serum
samples were collected at the same time. One follow-up serum
sample was taken from 42 patients after a 3-week interval,
while 21 patients had only a single serum sample taken. All
patients gave informed consent, and all serum samples
(n = 105) were stored at ) 80C.
Direct PCR-based detection assay
A commercially available PCR-based assay (ServiAmpli
Chlamydia pneumoniae; ServiBio, Meudon, France) was used
to detect C. pneumoniae directly, according to the manufac-
turer’s instructions. This assay is based on the ampliﬁcation of
C. pneumoniae chromosomal DNA, followed by colourimetric
detection of ampliﬁcation products on microplates coated with
speciﬁc probes. The target region of the primers and the probes
is the gene encoding the Omp2 protein of C. pneumoniae strain
IOL-207. The use of an internal control, which is ampliﬁed
with the same primers as the target DNA, allows detection of
PCR inhibitors. After DNA extraction, each sample was
subjected to two separate PCRs, one in the presence and one
in the absence of internal control. A positive control and two
negative controls (one extraction and one ampliﬁcation) were
included in each run. The diagnostic speciﬁcity of this PCR
assay was 100% in comparison with the MIF test (F. Betsou,
unpublished results).
Cloning and expression of the CPn0980 gene and gene
fragments
C. pneumoniae elementary body (EB) DNA was puriﬁed and
manipulated according to standard protocols [10]. The entire
CPn0980 gene was ampliﬁed with primers 0980P1 (5¢-AT-
GCTTAATCATGCTAAAAAG) and 0980P2 (5¢-CTCTTT-
TATTTTAGGAAGCTT) (Proligo, Paris, France), with Taq:Pfu
polymerase in an 8 : 1 ratio; the CPn0980 gene fragment coding
for the N-terminal region of the P54 protein (aa 1–183) with
primers 0980P3 (5¢-AATAATATTTAGAGGGAAGTTTCC)
and 0980P1 (5¢-ATGCTTAATCATGCTAAAAAG); the
CPn0980 gene fragment coding for the central region of the
P54 protein (aa 184–344) with primers 0980P5 (5¢-ATAAC-
CTCCAGAAATTCCATT) and 0980P6 (5¢-TGGTTAATTGAG-
GGTGAAGAA); and the CPn0980 gene fragment coding for
the C-terminal region of the P54 protein (aa 345–493) with
primers 0980P2 (5¢-CTCTTTTATTTTAGGAAGCTT) and
0980P4 (5¢-ACGGGACCAGGATTTAAGACT).
The resulting 1479-bp, 549-bp, 480-bp and 450-bp ampliﬁ-
cation products were cloned between the NcoI and PmeI sites
of the pBAD-TOPO vector (Invitrogen, Carlsbad, CA, USA),
which has single-stranded 3¢-thymidine overhangs. Competent
Escherichia coli TOP10 (F- F80lacZDM15 DlacX74 recA1 ara-
D139D(ara-leu)7697) cells were transformed with the resulting
plasmid constructs. Expression in E. coli was driven by the
araBAD promoter, and each recombinant protein was tagged
with a C-terminal 13-aa V5 epitope and a 6-histidine region.
Several clones with the expected inserts were obtained on
Luria Broth (LB) plates supplemented with ampicillin
100 mg ⁄L. Plasmids were digested with NcoI, PmeI, EcoRV,
BglII, XbaI and ScaI to ensure the correct orientation of the
inserts.
Production and puriﬁcation of the recombinant proteins
Transformed E. coli TOP10 cells (200-mL cultures) were
induced by L-arabinose 0.2% w ⁄v, grown to an OD600 of 1.5,
and centrifuged at 3000 g for 15 min. Pellets were stored at
) 80C until use. The cells were resuspended in 50 mM
NaH2PO4, 0.5 M NaCl, 10 mM imidazole, pH 8, incubated
with lysozyme 1 mg ⁄mL on ice for 30 min, sonicated, and
centrifuged at 3000 g for 15 min. The supernatant was
transferred to ProBond nickel-chelate afﬁnity puriﬁcation
columns (Invitrogen) and bound at room temperature for
1 h. The column was washed four times with 50 mM
NaH2PO4, 0.5M NaCl, 20 mM imidazole, pH 8. The His-
tagged protein was then eluted with 50 mM NaH2PO4,
0.5 M NaCl, 250 mM imidazole, pH 8. Elution fractions
(1 mL) were collected and analysed by SDS-PAGE. Protein
concentrations were determined by the Bradford method
with a bovine serum albumin standard [11]. The protein
preparation was stored at ) 80C until use.
Electrophoresis and immunoblotting
SDS-PAGE was carried out using ready-to-use polyacryla-
mide 4–15% w ⁄v gels for the PhastSystem (Pharmacia,
Uppsala, Sweden). The concentration of each antigen was
adjusted to 0.2 mg ⁄mL, and 1 lL was used for electrophor-
esis. After electrophoresis, the proteins were either stained
with Coomassie Blue or transferred to Hybond-C-super
membranes (Amersham, Little Chalfont, UK). After blocking,
the membrane was incubated with a 5 x 10)3 dilution of
monoclonal anti-V5-HRP antibody (Invitrogen), or with a 10)2
dilution of polyclonal mouse serum, at room temperature
for 1 h. Immunochemical detection was performed with
the enhanced chemiluminescence system (ECL system;
Amersham).
Dot-blotting
Hand-dropped dot-blots were made on nitrocellulose mem-
branes. The concentration of each antigen was adjusted to
0.2 mg ⁄mL, and 1 lL was used for dot-blotting to the
membrane. After blocking, the membrane was incubated with
a 10)2 dilution of polyclonal mouse serum at room tempera-
ture for 1 h. Immunochemical detection was performed with
the ECL system.
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P54 ELISA
Microtitre plates were coated with recombinant P54
(2 mg ⁄L) or recombinant P54 derivative (1 mg ⁄L), either
P54 N-terminal or P54 central region, and were then blocked
with skimmed milk 5% w ⁄v. Aliquots of sera, diluted 1 : 50
in phosphate-buffered saline (PBS) containing Tween-20
0.1% v ⁄v and NaCl 4% w ⁄v, were added to the wells,
and the plate was incubated at 37C for 60 min. The wells
were then washed three times with PBS containing Tween-
20 and incubated with a 1 : 1000 dilution of alkaline
phosphatase-conjugated goat antibody to human IgG, IgA
or IgM, or to mouse IgG (Sigma, Poole, UK). After
incubation for 60 min at 37C, the wells were washed three
times and the alkaline phosphatase substrate paranitrophe-
nylphosphate was added. After incubation at room tem-
perature for 20 min, the reaction was stopped by adding 3
M NaOH and the plates were read at a wavelength of
405 nm. A positive sample was deﬁned as a sample that
yielded an OD405 value at least two standard deviations
above the mean of 20 negative samples: i.e., OD405 > 0.12 for
IgG, > 0.11 for IgA, and > 0.1 for IgM [12]. Index values were
calculated as the OD405 cut-off.
Rheumatoid factor (RF) absorbent reagent (Dade Behring,
Deerﬁeld, IL, USA) was used to remove RF from human
serum. Diluted serum (1 : 10) was mixed with an equal
volume of undiluted reagent to give a 1 : 20 dilution. The
serum sample with RF absorbent was then diluted 2.5-fold in
serum dilution buffer to give a ﬁnal dilution of 1 : 50. Only
IgM antibodies detected in the treated serum were considered
to be true IgM antibodies.
P54 synthetic peptides and ELISA
The following N-biotinylated peptides, with N-terminal GG
linkers, were synthesised (NeoSystem, Strasbourg, France)
according to the CPn0980 sequence (GenBank AE001363):
BIOT-GGPNQDPDKAAHQVIHHLKQQVPSSL (P54 aa 369–
392; 26mer) and BIOT-GGLKFSYEILPGGSRGWRSSANLPI
(P54 aa 391–413; 25mer). These peptides correspond to the
C-terminal hydrophilic regions of the P54 protein, according
to Kyte-Doolittle plots [13], and do not contain cysteine
residues.
These synthetic peptides were analysed by ELISA, as
described above, with streptavidin-coated microplates. Each
peptide was used at a concentration of 1 mg ⁄L, and serum
samples were diluted 1 : 40. The cut-off OD405 value was 0.15
for both the aa 369–392 and the aa 391–413 peptide assays (two
standard deviations above the mean value obtained with 20
negative samples [12]).
Outer-membrane complex puriﬁcation
The C. pneumoniae IOL207 outer-membrane complex (OMC)
was prepared from puriﬁed EBs, essentially as described
previously [14]. Puriﬁed EBs were resuspended in PBS
containing sarcosyl 2% w ⁄v and 5 mM EDTA. The suspension
was sonicated brieﬂy, incubated at 37C for 30 min, and then
centrifuged for 2 h at 15 000 g. The resulting pellet was
resuspended in PBS containing sarcosyl 2% w ⁄v and 5 mM
MgCl2, sonicated, and treated with DNase 50 mg ⁄L and RNase
50 mg ⁄L at 37C for 30 min, before being centrifuged for 2 h at
15 000 g. The pellet was washed twice in PBS, resuspended in
PBS, and stored at ) 80C.
OMC IgG ELISA
OMC ELISA was performed as for the P54 ELISA described
above. Microplates were coated with OMC 5 mg ⁄L in PBS
containing Tween-20 0.1% v ⁄v. Serum samples were diluted
100-fold. The cut-off OD405 value was 0.4 (two standard
deviations above the mean value obtained with 20 negative
samples) [12].
Preparation of mouse sera
P54 preparations were adsorbed on aluminium hydroxide at a
ﬁnal aluminium concentration of 250 mg ⁄L.
To obtain sera from immunised mice, ten female (aged 3–4
weeks) Balb ⁄ c mice (Harlan, Gannat, France) were injected
subcutaneously with 250 lL of inactivated EB suspension,
puriﬁed OMC, or P54 preparation, twice at 2-week intervals.
This dose corresponded to 2 · 107 inactivated C. pneumoniae
EBs, 15 lg OMC, and 30 lg puriﬁed P54 or P54 derivatives.
Control animals were injected with 250 lL of control buffer
containing aluminium hydroxide. Mice were bled 5 weeks
after the ﬁnal injection, and pooled sera were tested to assess
the presence of circulating antibodies.
To obtain sera from infected mice, ten female (aged 3–4
weeks) Balb ⁄ c mice were infected intranasally with 250 lL of
C. pneumoniae EB suspension. The infectious dose correspond-
ed to 2 · 107 EBs. Mice were bled every week for a period of
7 weeks. The sera were pooled and tested for the presence of
circulating antibodies.
Statistical analysis
p values were calculated for correlations. Two-tailed p values
< 0.05 were considered to be signiﬁcant.
RESULTS
Production and puriﬁcation of recombinant
P54 protein and P54 derivatives
The CPn0980 gene was expressed in E. coli under
the control of the araBAD promoter. The optimal
concentration of L-arabinose for induction was
0.2% w ⁄ v, and bacteria grew for 4 h following
induction. Recombinant P54was produced as aV5-
His6-tagged protein and was puriﬁed by afﬁnity
chromatography. As expected, the recombinant
P54 appeared in bacterial suspension after, but not
before, induction with L-arabinose, and was detec-
ted by the anti-V5-HRP antibody. No proteolytic
degradation of the puriﬁed recombinant P54 pro-
tein was observed on immunoblots with themono-
clonal antibody. Clones with the correctly inserted
CPn0980 gene fragments coding for theN-terminal
and central regions of the P54 protein were also
obtained. However, all viable clones with the
fragment coding for the C-terminal region con-
tained the ampliﬁed gene fragment in the orienta-
tion prohibiting its expression. Even when the
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E. coli LMG194 strain was transformed, which
enables repressionof the arapromoter byglucose, it
was not possible to express stably the gene frag-
ment coding for the P54 C-terminal region.
The N-terminal and central fragments of the
P54 protein were puriﬁed by nickel chelate
afﬁnity chromatography. Immunoblotting was
carried out with the P54 whole protein, and with
the P54 N-terminal and central fragments with a
monoclonal anti-V5 tag antibody (Fig. 1).
Sensitivity and speciﬁcity of antibodies against
recombinant P54 and P54 synthetic peptides
The recombinant P54 ELISA assay detected IgG
and IgM antibodies in 21% and 8% of samples,
respectively. Nine (14.5%) of the 62 patients were
positive for C. pneumoniae according to PCR
analysis of throat swabs.
The sensitivity of anti-P54 IgG antibodies was
45% in relation to OMC ELISA. When the direct
PCR assay was taken as the standard, anti-P54
IgG and IgM antibodies had sensitivities of 55.5%
and 22.2%, respectively. Detection of either IgG
or IgM antibodies showed 66.7% sensitivity com-
pared with the direct PCR assay. Anti-P54 IgA
antibodies were detected in only two patients,
giving a sensitivity of anti-P54 IgA of 11.1% in
comparison with the PCR assay. Analysis of
follow-up serum samples revealed no cases of
IgG seroconversion.
The speciﬁcity of anti-P54 IgG was 100% in
relation to the OMC ELISA. When the direct PCR
test was taken as the standard, the speciﬁcities of
anti-P54 IgG, IgA and IgM were 84.9%, 98.1%
and 94.3%, respectively. The speciﬁcity of IgG
and IgM considered concomitantly was 79.2%
(Table 1).
To investigate the speciﬁcity of anti-P54 IgG
antibodies further, OMC ELISA index values
were compared with recombinant P54 ELISA
index values. A signiﬁcant correlation (r 0.73,
p < 0.001) was found between OMC IgG and
recombinant P54 IgG antibodies (Fig. 2).
Two synthetic peptides corresponding to the
hydrophilic C-terminal region of the native P54
protein were tested in ELISAs. The aa 369–392
and aa 391–413 peptides showed 15% and 20%
sensitivity, and 84.7% and 81.2% speciﬁcity,
respectively, compared with the PCR assay.
Among the nine patients who were positive for
C. pneumoniae according to PCR analysis of throat
swabs, three showed IgG seroconversion accord-
ing to both the aa 369–392 and the aa 391–413
synthetic peptide ELISAs, and one showed IgG
seroconversion according to the aa 391–413 ELISA
only.
Identiﬁcation of P54 homologues and sequence
alignment
The translated sequence of the C. pneumoniae
Cpn0980 gene was used in iterative queries of the
non-redundant protein database at the National
Center for Biotechnology Information using the
BLASTP program [15] with the BLOSSUM62
matrix and default gap costs for existence ) 10
and extension ) 0.5. Homologues (and their
SWISSPROT accession numbers) were identiﬁed
Fig. 1. Immunoblots of (1) Chlamydia pneumoniae element-
ary bodies, (2) C. pneumoniae outer-membrane complex, (3)
P54 protein, (4) P54 aa 184–344, and (5) P54 aa 1–183 with
(A) monoclonal anti-V5 antibody or (B) polyclonal anti-P54
serum. Molecular size markers correspond to 14 800,
28 201, 41 603, 55 004 and 68 406 Da, respectively.
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in the X-His dipeptidase from E. coli (P15288), the
histidine decarboxylase (HDC) from Vibrio angu-
illarum (Q56581), the histidine decarboxylase from
Morganella morganii (P05034), and the histidine
decarboxylase from Klebsiella pneumoniae (P28578).
Local alignments identiﬁed the aa 200–260 region
as being the most conserved.
Amino-acid sequences were aligned automat-
ically using the ClustalW program [16]. From the
alignment of ﬁve protein sequences, 17 positions
in the P54 aa 220–252 region corresponded to the
active-site region of HDC, and were deemed to be
aligned (Fig. 3).
Immunological properties of P54 derivatives
The ability of the polyclonal mouse sera, raised
against C. pneumoniae EBs, C. pneumoniae OMC,
the whole P54 protein, the P54 N-terminal frag-
ment and the P54 central fragment, to react with
the P54 protein and the P54 protein fragments
was tested by ELISA (Fig. 4) and by western and
dot-blotting (Fig. 1 and Fig. 5). Recombinant P54
ELISA yielded negative results with control
(non-immunised), anti-C. pneumoniae EB, and
anti-OMC sera. Anti-P54 whole protein sera also
yielded negative results. In contrast, anti-P54
protein fragment sera reacted positively, not only
against the homologous antigen, but also against
the whole P54 protein (Fig. 4).
Anti-P54 mouse sera reacted strongly with the
P54 protein and protein fragments, but not with C.
pneumoniae EBs (nor OMC) in western blots with
denatured antigens (SDS-PAGE). The serum raised
Table 1. Analytical sensitivity and speciﬁcity of P54 ELISAa
P54-positive P54-negative
IgG IgA IgM
IgG and ⁄ or
IgM
IgG and
IgM IgG IgA IgM
IgG and ⁄ or
IgM
IgG and
IgM
OMC-positive 9 ND ND 11 ND ND
OMC-negative 0 ND ND 34 ND ND
PCR-positive 5 1 2 6 4 8 7 3
PCR-negative 8 1 3 11 45 52 50 42
ND, not determined.
aOne or two follow-up serum samples from 62 patients were tested by recombinant P54 ELISA. Serum samples from 54 patients were tested by outer-membrane complex
(OMC) ELISA. Throat specimens were tested by PCR for Chlamydia pneumoniae. Numbers of patients are indicated.
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Fig. 2. Correlation between outer-membrane complex
(OMC)-speciﬁc antibodies and P54-speciﬁc IgG antibodies.
Fig. 3. Comparison of the active site region of Morganella morganii histidine decarboxylase (HDC), Klebsiella pneumoniae
HDC, Vibrio anguillarum HDC, Escherichia coli X-his dipeptidase and Chlamydia pneumoniae P54. Residues conserved in the
ﬁve sequences are marked by a double asterisk. Residues conserved in at least two sequences are marked by a single
asterisk. Similar residues are marked by double dots. The pyridoxal-P-binding lysine is marked by an exclamation point.
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against the whole P54 protein reacted with the
whole P54 protein and with the P54 protein
fragments (Fig. 1). Sera obtained from infected
mice did not react against the denatured P54 and
P54 derivatives (Table 2). However, when native
P54 and P54 derivatives were tested on dot-blots,
speciﬁc anti-P54 antibodies appeared 22 days after
infection, with the intensity of the observed signals
increasing up to day 50 post-infection. Further-
more, strong positive reactions against the P54
native antigens were observed with serum from
OMC-immunisedmice, whereas no reactions were
observed with serum from whole EB-immunised
mice (Fig. 5).
DISCUSSION
Accurate serological diagnosis of C. pneumoniae
infection has become essential because of its impli-
cation in chronic disease processes, especially
cardiovascular disease [17,18]. The recombinant
P54 protein is a C. pneumoniae-speciﬁc, immuno-
dominant protein. Western-blotting experiments
have shown that it is a speciﬁc diagnostic tool [9],
and this was conﬁrmed in the present study using
an ELISA system. The speciﬁcity was further
corroborated by the high correlation between
anti-OMC and anti-P54 antibodies, and the analyt-
ical sensitivity, evaluated by Campbell et al. [9] in
comparison with MIF, was conﬁrmed in the
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Fig. 4. (A) ELISA reactivities of polyclonal antisera from
mice immunised with P54, P54 aa 1–183 and P54 aa 184–
344 against homologous antigens. (B) ELISA of polyclonal
antisera from mice immunised with P54 against P54
protein, P54 aa 1–183 and P54 aa 184–344.
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Fig. 5. Dot-blots with (1) Chlamydia pneumoniae elementary
bodies (EBs), (2) C. pneumoniae outer-membrane complex
(OMC), (3) P54, (4) P54 N-terminal fragment, and (5) P54
central fragment. Dot-blots were incubated with sera from
mice infected with C. pneumoniae or immunised with
C. pneumoniae antigens. (A) sera from mice infected with
C. pneumoniae, 22 days after infection; (B) sera from mice
infected with C. pneumoniae, 50 days after infection;
(C) sera from mice immunised with C. pneumoniae EBs;
(D) sera from mice immunised with C. pneumoniae OMC;
(E) sera from mice immunised with P54; (F) sera from
control mice.
Table 2. Reactivity of Chlamydia pneumoniae-infected or
immunised mice sera against P54 and P54 fragments in
ELISA, western blot and dot-blot assays
Antigen
Chlamydia
pneumoniae
infection
Immunising antigen
EBs OMC P54 P54-Ca P54-Na
ELISA P54 ND – – – + +
P54-C ND – – – + +
P54-N ND – – – + +
Western blot EB – + + – – –
OMC – – – – ND ND
P54 – – – + + +
P54-C – – – + + +
P54-N – – – + + +
Dot-blot EB + + + + + + + +
OMC + + + – – –
P54 + – + + + + + + + +
P54-C + – + + + + + + + +
P54-N + – + + + + + + + +
EBs, elementary bodies; ND, not determined; OMC, outer-membrane complex.
aP54-C and P54-N correspond to P54 central and N-terminal fragments, respect-
ively.
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present study with an ELISA-based format and in
comparison with PCR.
The use of MIF as the reference test may lead to
an underestimation of the analytical sensitivity of
puriﬁed protein antigens, as MIF is based on
detection of antibodies against whole chlamydial
EBs, which harbour variable amounts of lipo-
polysaccharide (LPS), depending on the puriﬁca-
tion procedure. The use of PCR as the reference
test allows more accurate calculation of the
analytical sensitivity for detection of active (acute
or chronic) C. pneumoniae infections.
C. pneumoniae PCR has its own limitations,
perhaps associated with low C. pneumoniae DNA
copy numbers in clinical specimens such as naso-
pharyngeal swabs [19]. PCR sensitivity depends on
the relative DNA copy number in each sample,
which could explain the apparent discrepant PCR-
negative ⁄ IgM ELISA-positive results. The pres-
ence of circulating RF can give false-positive IgM
results [20]. Such false-positive IgM results were
eliminated from the P54 ELISA in this study. The
sensitivity of the IgG ⁄ IgM P54 ELISA in compar-
ison with the direct PCR detection method was
66.7%. It is noteworthy that no serological assay
can be 100% sensitive in comparison with a direct
detection test because of the time required before
induction of the speciﬁc humoral immune re-
sponse following the onset of infection.
Practically no IgA against recombinant P54 was
detected.Many infected individuals neverproduce
IgA antibodies, meaning that they may not be a
useful marker for chronic or acute C. pneumoniae
infections [21]. Therefore, the high speciﬁcity and
sensitivity of theP54ELISA, combinedwith the fact
that this protein can detect speciﬁc IgM antibodies
(allowing single-serum diagnosis of acute infec-
tion), makes it a valuable diagnostic tool that
recognises active C. pneumoniae disease, which
may allow acute and non-acute (resolved, chronic
or latent) infection to be distinguished.
It was not possible to obtain a clone with the
CPn0980 gene fragment coding for the C-terminal
region of the protein. Therefore, two synthetic
peptides from the corresponding region were
tested. Interestingly, both the aa 369–392 and aa
391–413 peptides were found to elicit synthesis of
speciﬁc IgG antibodies early in C. pneumoniae
infection, since IgG seroconversions could be
detected. Although antibodies against sequential
epitopes represented by P54 C-terminal peptides
could be detected, the sensitivity of such antibod-
ies, with respect to direct detection, was lower
than the sensitivity of antibodies against the
whole P54 antigen.
The function of the P54 protein remains un-
known, and it has been speculated that the P54 C-
terminal region might carry a function toxic to the
cell. A PROSITE search [22] revealed 36% similar-
ity between the whole P54 protein and the M20
family of decarboxylases, including histidine
decarboxylases (HDC) (Fig. 3). Furthermore,
C-terminal amino-acids 433–439 correspond to a
putative trans-membrane segment, according to
the DAS trans-membrane prediction method [23].
Histamine is a possible virulence factor for some
bacteria, e.g., the respiratory pathogenHaemophilus
inﬂuenzae [24], and it has been reported that C.
pneumoniae induces histidine decarboxylase (HDC)
production in mouse lungs [25]. If the P54 protein
induces HDC activity, it may produce histamine,
thus increasing the pH and affecting the host cell’s
metabolism, with possible physiopathological
implications.
Western blotting showed high titres of anti-P54
sera from immunised mice. Conformational con-
straints might explain why murine anti-P54 anti-
bodies failed to react with the native antigen in
ELISAs, whereas these sera reacted strongly with
denatured antigens on SDS-PAGE western blots.
The conformation of the puriﬁed recombinant
antigen might induce production of antibodies
against epitopes, which differ from immunoac-
cessible epitopes of the native antigen. Further-
more, sera from mice infected with C. pneumoniae,
and sera from mice immunised with C. pneumo-
niae OMC, failed to react with the denatured P54
and P54 fragments, but gave positive reactions
against the native P54 antigens. These results
suggest that the P54 antigen may be a minor
constituent of the C. pneumoniae OMC, and that
immunoaccessible epitopes of the native P54
antigen are mostly conformational. It was ob-
served that sera from mice immunised with C.
pneumoniae EBs recognised neither the denatured
nor the native P54 antigens. This may be caused
by a trans-membrane localisation of the protein,
with no immunoaccessible epitopes on the surface
of EBs, or because P54 is an antigen that is only
expressed in vivo. Further studies are needed to
unravel the regulation, function and topology of
P54, and to compare the immune responses
elicited after P54 active immunisation and after
C. pneumoniae infection.
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